ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.
Also called NCT01460446
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose diagnostic
- Phase
- Not applicable
- Enrolled
- 218 participants
- Sponsor
- Registry
-
NCT01460446
-
- Other papers using this trial's data
- Automated bolus advisor control and usability study (ABACUS): does use of an insulin bolus advisor improve glycaemic control in patients failing multiple daily insulin injection (MDI) therapy? [NCT01460446]
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Germany, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01460446. Randomized; no masking; primary purpose diagnostic. Start 2011-10 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2014-02-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
- Acronym
- ABACUS
- Condition
- Diabetes Mellitus, Type 1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Device)
- Aviva Expert blood glucose meter
- Intervention (Device)
- Aviva Nano blood glucose meter
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct01460446- Content hash
a0ab6299951b59e968817b162ac04426216038772eb56b5441bced923025c894